OHSU has been awarded two grants totaling $62 million from the National Center for Advancing Translational Sciences, to help bridge basic science and clinical research.
The first FDA-approved gene transfer therapy for patients with acute lymphoblastic leukemia will be available at a handful of approved hospitals, including OHSU Doernbecher.
Scientists have uncovered two related cytokines and associated genetic markers that may explain why some people develop progressive multiple sclerosis, or MS.